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ABSTRACT
Background. Psychiatric disorders are common in patients
with cancer. The impact of both psychiatric disorders and
psychiatric treatment on mortality in patients with cancer
needs to be established.
Materials and Methods. Nationwide claims data were ana-
lyzed. To investigate the association between psychiatric
disorders and mortality, 6,292 male and 4,455 female
patients with cancer who did not have a record of psychiat-
ric disorders before cancer onset were included. To exam-
ine the association between psychiatric treatment and
mortality, 1,467 male and 1,364 female patients with cancer
were included. Incident psychiatric disorder and receipt of
psychiatric treatment within 30 days from the onset of a
psychiatric disorder were the main independent variables.
Dependent variables were all-cause and cancer-related mor-
tality. Cox proportional hazards regression with time-
dependent covariates was used.
Results. The onset of psychiatric disorders was associated
with a significantly increased risk of mortality in both male
(all-cause hazard ratio [HR]: 1.55; cancer-related HR: 1.47)
and female patients with cancer (all-cause HR: 1.50; cancer-
related HR: 1.44) compared with patients with cancer with-
out psychiatric disorders. Both male and female patients
who received psychiatric treatment within 30 days of diag-
nosis of a psychiatric disorder had a lower risk of cancer-
related mortality (males, HR: 0.73; females, HR: 0.71) com-
pared with patients with cancer with psychiatric disorders
who did not receive psychiatric treatment.
Conclusion. Patients with cancer with newly diagnosed psy-
chiatric disorders had a higher mortality rate. Among these,
those who received psychiatric treatment showed lower
rates of mortality. Thus, early detection and early treatment
of psychiatric disorders in patients with cancer is needed.
The Oncologist 2020;25:e733–e742
Implications for Practice: The current study supplements the body of evidence supporting the association of psychiatric dis-
orders onset and treatment with cancer outcomes. Patients with cancer showed an increased risk of both all-cause and
cancer-related mortality upon psychiatric disorder onset. Among patients with newly diagnosed psychiatric disorders, those
who received psychiatric treatment showed lower cancer-related mortality. Thus, raising awareness of both the risk of psy-
chiatric disorders and the positive effects of psychiatric treatment on cancer outcomes is necessary among patients with
cancer, caregivers, and oncologists. Furthermore, it is necessary to adopt a multidisciplinary approach, encouraging patients
with cancer to undergo a neuropsychological assessment of their mental health status and receive appropriate and timely
psychological interventions.
INTRODUCTION
Cancer is a major issue for health authorities worldwide. Glob-
ally, it is estimated that in 2018, 18 million people were newly
diagnosed with cancer, and 9.6 million died of it [1]. In South
Korea, cancer is a major health problem, as it has remained
the leading cause of death for several decades. However, mod-
ern medical advances have increased the 5-year survival rate
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for patients with cancer from 41.2% between 1993 and 1995
to 70.7% between 2011 and 2015 [2].
As cancer survival rates increase, the mental health of
patients with cancer is increasingly prominent. A cancer
diagnosis is life-threatening and can have major psychologi-
cal effects. Patients’ awareness of their cancer diagnosis
could lead to psychological stress [3, 4]. Additionally, fear of
death, grief about losses, and worries about friends and
family could also contribute to psychological distress [5, 6].
Furthermore, radiotherapeutic or chemotherapeutic inter-
ventions can also affect patients’ mental status. Such psy-
chological distress could increase their vulnerability to
mental health problems, which may affect their health
behavior patterns and become diagnosable psychiatric dis-
orders [7, 8]. Thus, treating mental health is an important
clinical oncology issue [9].
Patients with cancer have higher rates of psychiatric dis-
orders than the general population [10, 11], including major
depression, anxiety, adjustment disorders, delirium, and
substance dependence disorders [9, 12]. Approximately
30%–50% of patients with cancer suffer from psychiatric
disorders [13]. Particularly, depression is two to four times
more common in patients with cancer than in the general
population [14, 15].
In patients with cancer, psychiatric distress needs to be
treated promptly, as delayed diagnosis or treatment may
incur side effects, which could affect their health outcomes
[16]. Untreated psychological distress is associated with
desire for death [17], disability [18], reduced quality of life
[19], aggravated pain [20], diminished ability to plan end of
life [21], and caregivers’ diminished psychosocial function-
ing [22] as well as prolonged hospitalization [19] and
reduced cancer treatment adherence [17]. Considering that
psychiatric disorders among patients with cancer may be
treatable [23], timely and appropriate approaches for diag-
nosis and treatment are needed to avoid negative
consequences.
Despite numerous studies in recent decades focusing on
depression and anxiety disorders in patients with cancer,
few have examined the whole spectrum of psychiatric disor-
ders or the effects of psychiatric treatment on clinical out-
comes. Considering the important impact of psychiatric
disorders on clinical outcomes, a study assessing psychiatric
disorders from a broader perspective in relation to cancer
mortality is warranted.
Thus, this study aimed to investigate the association
between psychiatric disorder onset and mortality among
patients with cancer. Moreover, we further investigated the
association between psychiatric treatment and mortality
among patients with cancer with psychiatric disorders.
MATERIALS AND METHODS
Data and Study Population
This study used National Health Insurance claims data from
2002 to 2013. This data set included records from
1,025,340 individuals, representing approximately 2.2% of
the Korean population [24]. Patients’ claims data are
recorded in four categories: insurance eligibility, medical
institutions’ data, health examination data, and medical
treatments (i.e., diagnosis code, medication, and treatment)
[24].
Patients with gastric (C16), colorectal (C18–C19), lung
(C34), and breast cancer (C50, only female)—the most fre-
quent cancers in South Korea—were identified using Inter-
national Classification of Disease 10th revision (ICD-10)
codes. Next, those who met the criteria for cancer, meaning
that they visited a medical institution under an ICD-10 C
code at least three times within a year and/or were hospi-
talized in a medical institution under a C code, were
selected [25]. We excluded patients whose year of cancer
diagnosis was 2002 (for wash-out) or 2013 (to allow at least
1-year follow-up). We also excluded 2,245 men and 4,679
women who had an ICD F code (F00–F99), which indicates
psychiatric disorder, prior to cancer onset, as we aimed to
identify patients with new-onset psychiatric disorders after
cancer diagnosis. After excluding patients aged under
20 and those insured by medical aid, the sample comprised
6,292 men and 4,455 women. To investigate the association
between psychiatric treatment and mortality, 1,515 men
and 1,389 women diagnosed with psychiatric disorders
after cancer onset were included. Among these, those who
died within 30 days of diagnosis of psychiatric disorder
were excluded from follow-up of psychiatric treatment.
Thus, the final sample was 1,467 men and 1,364 women
(supplemental online Fig. 1). This study was approved by
the Institutional Review Board of Yonsei University Health
System (Y-2018-0065).
Variables
The dependent variables were all-cause and cancer-related
mortality. Patients with death codes C16, C18–C20, C34,
and C50 (for women) were considered to have died of
cancer.
One of the main variables was postcancer psychiatric
disorder onset. New-onset psychiatric disorder was defined
as a psychiatric disorder diagnosis in a patient who had no
record of psychiatric disorder (ICD-10 F codes) before can-
cer onset. For analysis, F codes were reclassified into six
groups based on frequencies of psychiatric disorders among
patients with cancer [26]: (a) organic (including symptom-
atic) mental disorders (F00–F09); (b) mood disorders (F30–
F39); (c) anxiety disorders (F40–F42); (d) neurotic, stress-
related, and somatoform disorders (F43–F45, F48, F50);
(e) sleep disorders (F51, G47); and (f) other.
To investigate the effect of psychiatric treatment,
patients with cancer who underwent psychotherapy or
were prescribed psychiatric medication after psychiatric dis-
order onset were considered to have received psychiatric
treatment; the time limit for receiving such psychiatric
treatment was set as 30 days from psychiatric disorder
diagnosis. If patients did not undergo psychotherapy or
were not prescribed psychiatric medication within that time
span, they were considered to have not received psychiatric
treatment. The type of psychotherapy and medications
were identified from treatment codes and generic codes
(supplemental online Tables 1, 2).
To analyze the association between psychiatric diagno-
sis and mortality among patients with cancer, their age,
© AlphaMed Press 2020
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income, insurance status, disability status, residential area,
cancer site, Charlson comorbidity index, cancer treatment
method, type, location, existence of a neuropsychiatry
department in the diagnosing medical institution, and year
of cancer onset were controlled for. Additionally, to analyze
the association between psychiatric treatment and mortal-
ity, the type of psychiatric disorder and time to onset of
psychiatric disorder (time period between cancer onset and
psychiatric disorder onset) were controlled for (supplemen-
tal online Table 3).
Statistical Analysis
Chi-squared tests were conducted to examine the distribu-
tion of general characteristics in the sample by calculating
frequencies and percentages. Survival analyses were used
for the main models. When analyzing cancer-related mor-
tality, all-cause mortality was considered a competing risk.
First, a Cox proportional hazards model with time-
dependent covariates was conducted to examine the associ-
ation between psychiatric disorder onset and all-cause/can-
cer-related mortality among patients with cancer. Then, a
Cox proportional hazards model was used to analyze the
association between psychiatric treatment and all-cause/
cancer-related mortality among patients with cancer with
newly diagnosed psychiatric disorders.
Moreover, we conducted a sensitivity analysis by exclud-
ing patients newly diagnosed with organic (including symp-
tomatic) mental disorders in order to examine whether the
relationship between new-onset psychiatric disorders and
cancer-related mortality would still hold. Treatment for psy-
chiatric disorder was limited to within 30 days from the
date of psychiatric disorder diagnosis, and patients who
died within 30 days after psychiatric diagnosis were
excluded from the landmark analysis. Sensitivity analyses
were conducted by limiting treatment time to 3, 6, and
12 months from psychiatric diagnosis date. All statistical
analyses were conducted separately by gender and using
SAS software (version 9.4; SAS, Cary, NC).
RESULTS
Table 1 shows the distribution of general characteristics in
the study population. Of 6,292 male and 4,455 female
patients with cancer, 1,515 males and 1,389 females experi-
enced new-onset psychiatric disorders. In men, 588 patients
who developed new-onset psychiatric disorders died (all-
cause death rate: 74.0 per 1,000 person-years), with
447 dying of cancer (cancer death rate: 56.3 per 1,000
person-years). In women, 318 patients who developed new-
onset psychiatric disorders died (all-cause death rate: 39.2%
per 1,000 person-years), with 239 dying of cancer (cancer
death rate, 29.5% per 1,000 person-years; Table 1).
Regarding the type of psychiatric disorder, sleep disor-
der was the most frequent psychiatric diagnosis among
both male (n = 468, 7.4%) and female patients (n = 369,
8.3%). The second most frequent psychiatric diagnosis was
neurotic, stress-related, and somatoform disorders among
male patients (n = 313, 5.0%), and anxiety disorders among
female patients (n = 357, 8.0%). The third most frequent psy-
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(n = 288, 4.6%), and mood disorders among female patients
(n = 263, 5.9%). The average time from cancer diagnosis to
onset of psychiatric disorders was 877.7 days in men and
837.4 days in women (supplemental online Table 5).
Table 1 also shows the results of the Cox proportional
hazards model with time-dependent covariates for the
association between psychiatric disorder onset and mortal-
ity. Psychiatric disorder onset was associated with a signifi-
cantly increased risk of death in both men (all-cause
mortality hazard ratio [HR]: 1.55, p < .0001; cancer-related
mortality HR: 1.47, p < .0001) and women (all-cause mortal-
ity HR: 1.50, p < .0001; cancer-related mortality HR: 1.44,
p < .0001) compared with patients with cancer without psy-
chiatric disorders. This association was still observed after
excluding patients with organic (including symptomatic)
mental disorders in both men (all-cause mortality HR: 1.51,
p < .0001; cancer-related mortality HR: 1.43, p < .0001) and
women (all-cause mortality HR: 1.49, p < .0001; cancer-
related mortality HR: 1.42, p < .0001; supplemental online
Table 8).
Regarding the type of psychiatric disorder, the onset of
organic (including symptomatic) mental disorders was asso-
ciated with the highest risk of death in both men (all-cause
mortality HR: 2.01, 95% confidence interval [CI]: 1.53–2.65;
cancer-related mortality HR: 1.65, 95% CI: 1.17–2.31) and
women (all-cause mortality HR: 3.57, 95% CI: 2.57–4.96;
cancer-related mortality HR: 3.04, 95% CI: 2.07–4.46). In
men, the onset of mood disorders was associated with the
second highest risk of all-cause mortality (HR: 1.64, 95% CI:
1.31–2.06) and third highest risk of cancer-related mortality
(HR: 1.48, 95% CI: 1.14–1.94). Onset of sleep disorders was
associated with the third highest risk of all-cause mortality
(HR: 1.53, 95% CI: 1.32–1.77) and second highest risk of
cancer-related mortality (HR: 1.54, 95% CI: 1.31–1.80). In
women, onset of sleep disorders was associated with the
second highest risk of all-cause mortality (HR: 1.68, 95% CI:
1.36–2.07) and cancer-related mortality (HR: 1.69, 95% CI:
1.35–2.11).
When stratifying by cancer site, the highest risk of mor-
tality for patients with cancer with new-onset psychiatric
disorders was observed for those with gastric cancer among
both men (all-cause mortality HR: 2.05, p < .0001; cancer-
related mortality HR: 1.89, p < .0001) and women (all-cause
mortality HR: 1.87, p < .0001; cancer-related mortality HR:
1.81, p < .0001). In women, patients with breast cancer
showed the second highest mortality upon psychiatric dis-
order onset (all-cause mortality HR: 1.84, p = .0001; cancer-
related mortality HR: 1.77, p = .0012; Fig. 1).
Table 2 shows the association between receiving psychi-
atric treatment within 30 days of psychiatric diagnosis and
mortality. A total of 1,467 men were diagnosed with new-
onset psychiatric disorders. Of these, 1,097 received psychi-
atric treatment; among them, 397 patients died (all-cause
mortality), with 292 dying of cancer. Compared with those
who did not receive treatment for new-onset psychiatric
disorders, those who received treatment showed lower HR
(0.81, p = .0376). Regarding the type of psychiatric treat-
ment, only pharmacotherapy showed a statistically signifi-
cant association with mortality (all-cause HR: 0.79,
p = .0277; cancer-related mortality HR: 0.71, p = .0039).
Figure 1. Hazard ratios for mortality associated with newly diagnosed psychiatric disorder by cancer site.
Abbreviation: CI, confidence interval.
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In women, 1,364 patients were diagnosed with psychiat-
ric disorders after cancer onset (Table 2). Of these, 1,052
patients received psychiatric treatment; among them,
216 died (all-cause mortality), with 155 dying of cancer.
Compared with those who did not receive treatment for
new-onset psychiatric disorders, those who received psychi-
atric treatment showed lower HR for cancer-related mortal-
ity (0.71, p = .0393).
When stratifying by cancer sites, only men with colorec-
tal cancer showed lower rates of cancer-related mortality
(HR: 0.42, 95% CI: 0.22–0.80) compared with patients with
colorectal cancer who did not receive psychiatric treatment
(Fig. 2). Figure 3 shows the results of the sensitivity analy-
sis. When the time between psychiatric disorder onset and
receipt of psychiatric treatment increased, the mortality risk
also increased, although this association was not statisti-
cally significant.
DISCUSSION
The results of the present study showed that both male
and female patients with cancer with new-onset psychiatric
disorders had a higher risk of mortality compared with
patients with cancer without psychiatric disorders. Regard-
ing the cancer site, both men and women with gastric can-
cer, and women with breast cancer, with new-onset
psychiatric disorders showed the highest mortality rates.
Organic (including symptomatic) mental disorders, mood
disorders, and sleep disorders were associated with a
higher risk of mortality in both genders compared with
those without new-onset psychiatric disorders.
Prior studies have shown that depression, schizophre-
nia, substance-abuse disorders, and other psychotic disor-
ders increase the mortality rate of patients with cancer
[27–30]. Furthermore, poor quality of cancer treatment
could help explain their findings [31–35]. For example, delir-
ium produces symptoms of attention deficit and loss of
awareness, which affects communication with family mem-
bers and impedes participation in treatment-related deci-
sions, symptom assessment, and counseling; together,
these factors in turn may aggravate the burden of symptom
distress [36, 37]. Moreover, patients with psychiatric disor-
ders tend to lack social support [38, 39]. Previous studies
have demonstrated that patients with low quality or degree
of social support and supportive relationships have lower
survival rates [38, 39]. Thus, the combination of these fac-
tors may adversely affect cancer treatment and render
patients more vulnerable to negative cancer outcomes.
According to our results stratified by cancer site, both men
and women with gastric cancer and women with breast cancer
diagnosed with new-onset psychiatric disorders showed the
highest mortality rate compared with patients with cancer
without psychiatric disorders. Usually, because of the comorbid
dumping syndrome (in the case of gastrectomy) or gastrointes-
tinal reflux, gastric cancer adversely affects eating behavior as
well as emotional and physical functioning [40]. On the other
hand, breast cancer produces serious mental health problems
among women, who may experience sexual dysfunction,
Figure 2. Hazard ratios for mortality associated with receiving psychiatric treatment within 30 days from the diagnosis of psychiatric
disorder among patients with cancer with newly diagnosed psychiatric disorder by cancer site.
Abbreviation: CI, confidence interval.
© AlphaMed Press 2020
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concerns about infertility, menopausal syndrome, and emo-
tional distress, including anxiety and depression, due to the
negative effects of mastectomy on their body image [41–43].
Furthermore,Watson et al. [30] found that patients with breast
cancer who reported feelings of hopelessness or helplessness
were more likely to die compared with those who did not
experience such negative emotions.
In the current study, patients with cancer with newly diag-
nosed psychiatric disorders after cancer diagnosis showed
lower rates of mortality when they received psychiatric treat-
ment. Both men and women who received psychiatric treat-
ment within 30 days of psychiatric diagnosis showed lower
cancer-related mortality compared with those with psychiatric
disorders who did not receive treatment. Previous studies on
this association have yielded conflicting results, with some
indicating that psychotherapy was not associated with cancer
outcomes, contrary to the present results [44–47]. Neverthe-
less, in one study, although group therapy had no association
with survival, it improved quality of life [46]. Numerous other
studies showed positive associations between psychiatric
treatment and cancer outcomes. For instance, it has been
suggested that pharmacotherapy can potentially reverse the
severity of cognitive symptoms in depressed patients with
cancer [48]. A recent study of patients with cancer found that
depressive symptoms were associated with longer duration
of hospitalization, but only in patients not taking antidepres-
sant medication [49]. Therefore, antidepressants could alleviate
negative outcomes of patients with cancer with depression.
Furthermore, some antidepressants, for example, mirtazapine,
may also alleviate some chemotherapy-related symptoms, such
as nausea or cachexia-anorexia [50].
In South Korea, stereotypes and prejudice may lead to
insufficient awareness of the mental health needs of patients
with cancer. Consequently, the optimal intervention timing
may be overlooked [26]. Moreover, patients with cancer are
vulnerable to impaired mental health, and delay or absence
of treatment for psychiatric disorders may worsen their
impact on cancer outcomes. Studies on early psycho-
oncologic interventions, such as education about coping skills,
demonstrated effective ways to control psychological distress,
including depression and anxiety [51, 52]; hence, early identi-
fication and treatment of psychological disorders is crucial.
The present results have several implications. First,
awareness about the risk of psychiatric disorders should be
promoted among patients with cancer, their caregivers, and
oncologists. Because some psychiatric disorders, including
depression and anxiety, could be regarded as natural conse-
quences of cancer treatment, or may even be difficult to
distinguish from chemotherapy side effects, many patients,
caregivers, and oncologists tend to neglect these symptoms
and leave them untreated [53]. Thus, education about psy-
chiatric symptoms and disorders needs to be provided at
the cancer diagnosis stage or during treatment. Second, it is
necessary to promote psychiatric consultation. Even if
patients desire psychological support [54], it may be diffi-
cult to recognize their psychological symptoms, and only a
small proportion of patients with cancer who experience
psychological distress receive psychiatric interventions [55].
Therefore, physicians should be aware of the types of
patients who may be vulnerable to psychological distress
and refer them for neuropsychiatric assessment/interven-
tion in a timely manner. This requires a multidisciplinary
approach; by connecting the oncology and neuropsychiatry
departments and encouraging patients to undergo consulta-
tions, the mental health status of patients with cancer could
be screened, and appropriate interventions could be
offered. Third, considering that the average time from can-
cer diagnosis to onset of psychiatric disorders was
2–3 years, it is important to pay attention to patients with
cancer who are in the survivorship period.
Limitations
The results of this study should be interpreted with caution
because of several limitations. First, the limitations of
administrative data due to potential inaccuracies have been
previously discussed. For instance, ICD-10 codes in cohort
data may not always represent patients’ real disease status
because their primary purpose is to facilitate patients’
health insurance claims [24]. However, a previous study
demonstrated a 70% correspondence between claims codes
and medical record codes [56].
Second, because our study used administrative data,
potential confounders that could affect mortality, such as
health-related behaviors (e.g., smoking, drinking, and physi-
cal activity) and presence of caregivers, could not be con-
trolled for, as this information was not available.
Third, the exact stage of cancer could not be analyzed
because the data set did not contain this information. Thus, it
could be that patients with new-onset psychiatric disorders
were more ill and therefore had higher mortality. Similarly,
patients with more advanced illness may have been less likely
to receive psychiatric treatment and therefore also had
increased mortality. However, to compensate for this limitation,
cancer treatment methods (operation only, chemotherapy or
Figure 3. Hazard ratios for mortality with psychiatric treatment
receipt by time limit for receiving psychiatric treatment from
the diagnosis of psychiatric disorder.
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radiotherapy before or after operation, and chemotherapy or
radiotherapy only) were considered to approximately gauge
cancer severity. However, this system may be imprecise
because some chemotherapy drugs were not covered by the
National Health Insurance during the study period.
Fourth, psychiatric disorder severity could not be
included in this model because disorders were identified
and classified using ICD-10 codes. Furthermore, owing to
the characteristics of the claim data, only patients who vis-
ited medical institutions with psychiatric symptoms and
were diagnosed using a fixed set of psychiatric disorder
classification codes were considered. Therefore, patients
who exhibited psychiatric distress but did not visit medical
institutions were not included. Thus, some study partici-
pants’ mental health status may have been misrepresented.
Fifth, psychotherapy was also identified and classified
using treatment codes because medical records were not
available. Therefore, it was impossible to determine the
exact form of psychotherapy, therapy duration, who partici-
pated in therapy sessions, and other features.
Sixth, some psychiatric medications can target multiple
symptoms; however, we could not separate them exactly.
Seventh, we could not classify “other” psychiatric disor-
ders according to their type because of the small numbers
of patients diagnosed in our sample.
Lastly, this study defined patients with newly diagnosed
cancer and new-onset psychiatric disorders using a set wash-
out period. However, this relied on an assumption because
records preceding 2002 do not exist in an electronic format.
Therefore, potential contamination of the inclusion criteria in
the study population cannot be ruled out.
CONCLUSION
The current study supplements the body of evidence
supporting the association of psychiatric disorder onset and
treatment with cancer outcomes. This study found that
patients with cancer with newly diagnosed psychiatric disor-
ders showed higher mortality rates than those without a
psychiatric diagnosis, regardless of gender. Furthermore,
patients with cancer with newly diagnosed psychiatric disor-
ders showed a lower risk of mortality when they received
psychiatric treatment compared with those who did not
receive it. Patients with cancer are vulnerable to psychiatric
disorders, which can hamper the healing process and pro-
duce negative outcomes. Psychiatric treatment can be
effective in alleviating the effects of psychiatric disorders
among patients with cancer. Thus, raising awareness of
both the risk of psychiatric disorders among patients with
cancer and the positive effects of psychiatric treatment on
cancer outcomes is necessary among patients with cancer,
caregivers, and oncologists. Furthermore, through a multi-
disciplinary approach, encouraging patients to undergo neu-
ropsychological assessment of their mental health and
receive appropriate and timely psychological treatment is
important to reduce the impact of psychiatric disorders on
cancer outcomes. Further studies need to be conducted
using information about the exact cancer stage to better
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